These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34829820)

  • 1. Targeted Therapies in Cancer: To Be or Not to Be, Selective.
    Montoya S; Soong D; Nguyen N; Affer M; Munamarty SP; Taylor J
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops.
    von Manstein V; Yang CM; Richter D; Delis N; Vafaizadeh V; Groner B
    Curr Signal Transduct Ther; 2013 Dec; 8(3):193-202. PubMed ID: 25045345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
    Kelly CM; Buzdar AU
    Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
    Sarmento-Ribeiro AB; Scorilas A; Gonçalves AC; Efferth T; Trougakos IP
    Drug Resist Updat; 2019 Dec; 47():100646. PubMed ID: 31733611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors targeting the cancers.
    Liu GH; Chen T; Zhang X; Ma XL; Shi HS
    MedComm (2020); 2022 Dec; 3(4):e181. PubMed ID: 36254250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.
    van der Kuip H; Wohlbold L; Oetzel C; Schwab M; Aulitzky WE
    Am J Pharmacogenomics; 2005; 5(2):101-12. PubMed ID: 15813673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
    Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
    Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.
    Ahronian LG; Corcoran RB
    Genome Med; 2017 Apr; 9(1):37. PubMed ID: 28431544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
    Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
    Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.
    Dhawan A; Nichol D; Kinose F; Abazeed ME; Marusyk A; Haura EB; Scott JG
    Sci Rep; 2017 Apr; 7(1):1232. PubMed ID: 28450729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to tyrosine kinase inhibitors: calling on extra forces.
    Cools J; Maertens C; Marynen P
    Drug Resist Updat; 2005 Jun; 8(3):119-29. PubMed ID: 15869901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.
    Aftimos PG; Wiedig M; Langouo Fontsa M; Awada A; Ghanem G; Journe F
    Int J Oncol; 2013 Sep; 43(3):919-26. PubMed ID: 23835698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.